ACAD
37.43
-0.2
-0.53%
AEMD
1.815
+0.06
+3.4076%
APRI
1.66
+0.005
+0.2840%
ARNA
24.83
-0.28
-1.12%
ATEC
2.2
+0.07
+3.29%
CNAT
5.32
-0.21
-3.80%
CRXM
0.151
0.00
0.00%
CYTX
0.373
-0.037
-9.0576%
DXCM
69.38
-0.12
-0.17%
GNMK
9.47
-0.09
-0.94%
HALO
16.595
-0.005
-0.030%
ILMN
200.51
+0.27
+0.13%
INNV
0.099
-0.001
-1.4014%
INO
6.17
-0.12
-1.91%
ISCO
1.95
+0.15
+8.33%
ISIS
57.56
0.00
0.00%
LGND
135.18
-0.63
-0.46%
LPTN
2.93
-2.93
-100.00%
MBVX
0.64
-0.1
-13.5270%
MEIP
2.74
0.00
0.00%
MNOV
6.073
+0.193
+3.2857%
MRTX
9.85
-0.5
-4.83%
MSTX
0.13
-0.01
-5.28%
NBIX
58.76
-0.07
-0.12%
NUVA
54.23
-0.38
-0.70%
ONCS
0.96
-0.02
-2.0410%
ONVO
2.01
0.00
0.00%
OREX
2.287
+0.002
+0.0744%
OTIC
3.25
-0.2
-5.80%
QDEL
43.04
-0.09
-0.21%
RCPT
231.96
0.00
0.00%
RGLS
1.29
-0.03
-2.27%
RMD
77.36
+0.04
+0.05%
SCIE
0
0.00
0.00%
SPHS
2.2
-0.04
-1.79%
SRNE
1.775
-0.025
-1.389%
TROV
0.691
+0.011
+1.5586%
VICL
2.41
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
13.85
+0.8
+6.13%
ACAD
37.43
-0.2
-0.53%
AEMD
1.815
+0.06
+3.4076%
APRI
1.66
+0.005
+0.2840%
ARNA
24.83
-0.28
-1.12%
ATEC
2.2
+0.07
+3.29%
CNAT
5.32
-0.21
-3.80%
CRXM
0.151
0.00
0.00%
CYTX
0.373
-0.037
-9.0576%
DXCM
69.38
-0.12
-0.17%
GNMK
9.47
-0.09
-0.94%
HALO
16.595
-0.005
-0.030%
ILMN
200.51
+0.27
+0.13%
INNV
0.099
-0.001
-1.4014%
INO
6.17
-0.12
-1.91%
ISCO
1.95
+0.15
+8.33%
ISIS
57.56
0.00
0.00%
LGND
135.18
-0.63
-0.46%
LPTN
2.93
-2.93
-100.00%
MBVX
0.64
-0.1
-13.5270%
MEIP
2.74
0.00
0.00%
MNOV
6.073
+0.193
+3.2857%
MRTX
9.85
-0.5
-4.83%
MSTX
0.13
-0.01
-5.28%
NBIX
58.76
-0.07
-0.12%
NUVA
54.23
-0.38
-0.70%
ONCS
0.96
-0.02
-2.0410%
ONVO
2.01
0.00
0.00%
OREX
2.287
+0.002
+0.0744%
OTIC
3.25
-0.2
-5.80%
QDEL
43.04
-0.09
-0.21%
RCPT
231.96
0.00
0.00%
RGLS
1.29
-0.03
-2.27%
RMD
77.36
+0.04
+0.05%
SCIE
0
0.00
0.00%
SPHS
2.2
-0.04
-1.79%
SRNE
1.775
-0.025
-1.389%
TROV
0.691
+0.011
+1.5586%
VICL
2.41
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
13.85
+0.8
+6.13%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Green Cross to Present at 34th Annual J.P. Morgan Healthcare Conference

January 5, 2016 – 3:00 am

YONGIN, South Korea, Jan. 5, 2016 /PRNewswire/ — Green Cross Corporation (Green Cross) (KRX: 006280), a South Korean biopharmaceutical company, announced today that BG Rhee, Ph. D., President of Green Cross Holdings, will present at 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, 13 January 2016 at 2:30 pm PT. Dr. Rhee will provide an update on the business and the progress of Green Cross’ pipeline at the conference.

About Green Cross Corporation

Green Cross Corporation is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, Green Cross is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions for nearly half a century.

SOURCE Green Cross

Oncology’s Future: Liquid Biopsies and the Heterogeneity of Cancer

January 5, 2016 – 2:00 am

We have known for some time that cancer is not a static, monolithic disease. Instead, we now think of cancer as heterogeneous. Each patient’s cancer may arise from widely dissimilar origins, even in…

[[Click headline to continue reading.]]

Lab Space on a Navy Ship, And Other Creative Solutions for NY Biotech

January 4, 2016 – 10:01 pm

I was a management consultant in a former life, and was trained in that role to always have three arguments to support any conclusion. But having spent the last six months living and breathing…

[[Click headline to continue reading.]]

Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 11

January 4, 2016 – 2:05 pm

DUBLIN, Jan. 4, 2016 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Bruce C. Cozadd, chairman and chief executive officer, will provide an overview of the company and provide a business and financial update at the conference on Monday, January 11, 2016 at 10:00 a.m. PST / 6:00 p.m. GMT.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharma.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company’s website at www.jazzpharma.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S.  For more information, please visit www.jazzpharma.com.

Logo – http://photos.prnewswire.com/prnh/20150930/272253LOGO

 

SOURCE Jazz Pharmaceuticals plc

Tyrogenex to Present at 8th Annual Biotech Showcase(TM)

January 4, 2016 – 8:17 am

– Company to provide corporate update at San Francisco investor forum –

NEEDHAM, Mass. and PALM BEACH GARDENS, Fla., Jan. 4, 2016 /PRNewswire/ — Tyrogenex, a privately held biopharmaceutical company, today announced it will present a company update during the eighth annual Biotech Showcase™ at the Parc 55 Hilton hotel in San Francisco.

Tyrogenex CEO Michael D. Webb will present a company update on Jan. 11, 2016, at 1:45 pm PST in the Hearst room.

Tyrogenex is developing X-82, an orally-administered dual vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor, for wet age-related macular degeneration (wet AMD) and solid tumors.

For wet AMD, one of the leading causes of blindness for people over the age of 50 that affects more than 1.5 million Americans, the company is enrolling patients in the APEX phase 2 trial for the treatment of wet AMD. This year, Tyrogenex has been invited to present phase 1 data that shows X-82 is well tolerated and has the potential to improve visual acuity at five prestigious ophthalmology conferences: American Academy of Ophthalmologists, the 15th Eurentina Congress, the 12th International Symposium on Ocular Pharmacology and Therapeutics Clinical Conference, Association for Research in Vision and Ophthalmology and Angiogenesis.

In oncology, proof-of-concept studies indicate efficacy and safety of X-82 in solid tumors and that its low toxicity is uniquely suited for combination regimens. It’s a potent CSF1R inhibitor, making it a good candidate to combine with certain immunotherapies, such as anti-PD1 or PD-L1 mAb. 

Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group.

About Tyrogenex
Tyrogenex is a biopharmaceutical company focused on improving the lives of patients with wet AMD and solid tumors by discovering medicines to help provide additional treatment options. Tyrogenex’s lead compound is X-82. For more information, visit www.tyrogenex.com

About X-82
Tyrogenex’s lead compound is X-82.  X-82 inhibits both VEGF and PDGFR. Tyrogenex believes X-82 targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis and inflammation.  X-82 is currently being evaluated for wet AMD and solid tumors.

About Wet AMD
AMD is the leading cause of blindness for people over the age of 50 in the United States and Europe. There are two forms of the disease, namely “dry” and “wet” AMD. Wet AMD is characterized by the growth of new blood vessels into the central region of the retina. These new and abnormal blood vessels cause severe central vision loss due to retinal damage caused by leakage of the blood vessels and subsequent scar formation.

Forward-Looking Statements
This press release contains forward-looking statements that are based on company management’s current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.

Corporate Contact:
Teri Swift
Tyrogenex Corporate Communications
(561) 406-9705
teri@tyrogenex.com

Logo – http://photos.prnewswire.com/prnh/20151113/287174LOGO

SOURCE Tyrogenex

Halozyme Enters Into Agreement For $150 Million Non-Dilutive Royalty-Backed Debt Financing

January 4, 2016 – 6:30 am

SAN DIEGO, Jan. 4, 2016 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has entered into a $150 million credit agreement, secured by future royalties of ENHANZE products, received only from Halozyme’s collaborations with Roche and Baxalta.

“This transaction allows us to continue to execute our two pillar strategy supporting the initiation of our phase 3 study in pancreatic cancer, ongoing studies in non-small cell lung and gastric cancers, and start of our planned trial in breast cancer in collaboration with Eisai,” said Dr. Helen Torley, president and chief executive officer of Halozyme.  “This opportunity for non-dilutive financing further demonstrates how our ENHANZE platform can drive value, and is additive to the $25 million upfront payment from the recently announced licensing and collaboration agreement with Eli Lilly.”

The debt transaction is expected to close in January 2016.  The financing will be facilitated through investment funds managed by Pharmakon Advisors and Athyrium Capital Management.  “We are pleased to partner with Halozyme in this transaction,” said Martin Friedman, managing member of Pharmakon Advisors. “We believe Halozyme’s ENHANZE technology adds tremendous value to biologic products as demonstrated by the strength of Halozyme’s collaborations with Roche and Baxalta.”  As part of the financing structure, Halozyme formed a wholly-owned subsidiary, Halozyme Royalty LLC (“Halozyme Royalty”), which, subject to satisfaction of certain closing conditions, will borrow $150 million at a per annum interest rate of 8.75 percent plus the three-month LIBOR rate. Under the terms of the loan, the three-month LIBOR rate is subject to a floor of 0.70 percent and a cap of 1.50 percent. 

On the closing date, Halozyme will transfer to Halozyme Royalty the right to receive certain royalty payments from the commercial sales of Herceptin SC and MabThera SC under Halozyme’s collaboration agreement with Roche and from the commercial sales of Hyqvia under Halozyme’s collaboration agreement with Baxalta.  Halozyme will continue to record and report royalty revenues over the term of the loan, using the payments from the collaboration agreements as the source of funds to repay the principal and interest on the loan.  Milestone payments received under any current or future collaboration agreements are excluded from the transaction.

Under the terms of the credit agreement, Halozyme Royalty will not be required to apply any of the royalty payments to repay the loan during 2016.  All interest accrued in 2016 will be capitalized and added to the outstanding balance of the loan.  Halozyme Royalty will only be required to apply 50 percent of royalty payments received in 2017 to make principal and interest payments subject to quarterly caps set forth in the credit agreement. Thereafter, subject to quarterly caps set forth in the credit agreement, Halozyme Royalty will apply all of the royalty payments received to repay outstanding principal and interest on the loan. If royalty payments available to repay the loan are insufficient to pay accrued interest due on any quarterly payment date, the unpaid interest will be capitalized and added to the outstanding principal balance of the loan.  Royalty payments received in excess of the quarterly caps will be retained by Halozyme Royalty and distributed to Halozyme.  Loan-related expenses will be deducted from the royalty payments before such amounts are applied to the loan or distributed to Halozyme Royalty.

The final maturity date of the loan will be the earlier of (i) the date when the principal amount and accrued interest are paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the collaboration agreements with Roche and Baxalta and (iii) December 31, 2050.  Repayment of the loan is the sole obligation of Halozyme Royalty and is intended to be non-recourse to Halozyme Therapeutics, Inc. and its other subsidiaries.

About Halozyme

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of PEGPH20, the expected timing of consummation of the royalty-based financing transaction, the anticipated timing and amount of costs for clinical trials and expectations of the company’s funding levels that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected problems in satisfying conditions to closing the royalty-based financing transaction, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com

Chris Burton
858-704-8352
ir@halozyme.com

Logo – http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

 

SOURCE Halozyme Therapeutics, Inc.

MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer

January 4, 2016 – 6:00 am

Patient Enrollment in Phase I Trial Expected to Begin in Early 2016

SAN DIEGO, Jan. 4, 2016 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces that it has received notice from the U.S. Food and Drug Administration (FDA) authorizing the initiation a Phase I clinical trial with HuMab-5B1 as a therapeutic treatment for pancreatic cancer.  The Company filed an Investigational New Drug (IND) application for its lead fully human antibody product on November 30, 2015.  Patient enrollment in the Phase I clinical trial is expected to begin at multiple investigational sites in early 2016.

The Phase I trial will evaluate the safety, tolerability and pharmacokinetics of HuMab-5B1 as a single agent or in combination with a standard of care chemotherapy regimen in subjects with metastatic pancreatic cancer.  The first cohort of patients will be enrolled in a traditional dose escalation regimen to assess safety and determine the optimal dose of the antibody.  A second patient cohort will establish the safety and optimized dose of the antibody when administered with a standard of care chemotherapy.   Two additional patient cohorts will be administered the optimized dose of antibody as a single agent, or in combination with a standard of care chemotherapy regimen, for the treatment of patients with pancreatic cancer. 

David Hansen, MabVax’s President and Chief Executive Officer, said, “We are delighted with the FDA’s expeditious response to our IND filing.  We intend to begin the dose escalation portion of this trial as soon as possible and anticipate reporting early safety assessment and determination of a maximum tolerated dose by mid-year 2016. This significant interim milestone will enable us to move into the combination therapy and monotherapy portions of the trial that we expect will provide important pharmacological data. This milestone could also have a positive impact on our future commercial and corporate development activities.”

MabVax plans to file a second IND application for a HuMab-5B1 PET imaging agent and, subject to FDA authorization, will begin this Phase I trial in patients with pancreatic cancer in early 2016.  89Zr-HuMab-5B1, which is the antibody combined with a radio-label as a novel PET imaging agent, has demonstrated high image resolution of tumors in established xenograft animal models, making it attractive as a potential companion diagnostic for the HuMab-5B1 therapeutic product. 

“Data generated in the early portions of these two Phase I trials could demonstrate important initial safety, targeting specificity and utility of the HuMab-5B1 antibody in patients with this devastating disease,” added Mr. Hansen. “We are excited about the potential applicability of our dual-product development approach in other cancers with HuMab-5B1, as well as with follow-on antibodies under development at MabVax.”

About HuMab-5B1:

MabVax’s HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center.  In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers.  The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer. 

About MabVax:

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of vaccine and antibody-based products and vaccines to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company’s proprietary vaccines. MabVax also has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center.  MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof-of-concept Phase II multicenter clinical trials, and a vaccine targeting neuroblastoma that will be ready for a Phase II clinical trial in 2016. Additional information is available at www.mabvax.com.

Forward Looking Statements:

This press release contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s filing on an IND and product development pipeline.  We have no assurance that all of the product development pipeline will be fully developed by the Company.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended and supplemented from time to time and  the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact:

Jody Cain

Senior Vice President

LHA

310-691-7100

jcain@LHAI.com 

Robert B. Prag

Scott Wilfong

President 

President

The Del Mar Consulting Group, Inc. 

Alex Partners, LLC                             

858-794-9500 

425-242-0891

bprag@delmarconsulting.com 

scott@alexpartnersllc.com

 

SOURCE MabVax Therapeutics Holdings, Inc.

Ionis Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference

January 4, 2016 – 5:00 am

CARLSBAD, Calif., Jan. 4, 2016 /PRNewswire/ — Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, today announced that management will present a company overview at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 2:30 p.m. PT in San Francisco, CA.

A live audio webcast of the presentation will be available on the “Investors & Media” section of the Company’s website, www.ionispharma.com. A replay will be available on the Ionis website within 48 hours and will be archived for a limited time.

ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development.  Drugs currently in Phase 3 development include volanesorsen, a drug Ionis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug Ionis is developing with GSK to treat patients with all forms of TTR amyloidosis; and nusinersen, a drug Ionis is developing with Biogen to treat infants and children with spinal muscular atrophy. Ionis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.

IONIS’ FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Ionis Pharmaceuticals’ business and the therapeutic and commercial potential of Ionis’ technologies and products in development, including nusinersen, IONIS-TTRRx and volanesorsen.  Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2014, and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.

In December, 2015, the Company changed its name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc.  In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc.  Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc. 

Logo – http://photos.prnewswire.com/prnh/20151221/317736LOGO

 


SOURCE Ionis Pharmaceuticals, Inc.

Luminex Corporation To Present At J.P. Morgan Healthcare Conference

December 31, 2015 – 6:30 am

AUSTIN, Texas, Dec. 31, 2015 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 34th Annual J.P. Morgan Healthcare Conference to be held January 11-14, 2016, in San Francisco, CA.

The investor presentation will begin at 8:30 a.m. Pacific time (11:30 a.m. Eastern time) on Thursday, January 14, 2016.  The presentation will be webcast live and may be accessed at Luminex Corporation’s website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived for six months on the website using the ‘replay’ link.

ABOUT LUMINEX CORPORATION

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex’s technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.

Contacts:

Harriss T. Currie

Sr. Vice President, Finance and CFO

512-219-8020

hcurrie@luminexcorp.com

Matt Scalo

Sr. Director, Investor Relations

512-219-8020

mscalo@luminexcorp.com

Logo – http://photos.prnewswire.com/prnh/20150201/172702LOGO

 

SOURCE Luminex Corporation

Synthetic Biology Primer: In Conversation With Richard Kitney, Part 1

December 31, 2015 – 3:00 am

“Synthetic biology” has always been a puzzling term to me. Prosthetic limbs are synthetic. Knee replacements are synthetic. Splicing the gene from one organism into another, a practice…

[[Click headline to continue reading.]]